Mostrar o rexistro simple do ítem
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
dc.contributor.author | Mena, Álvaro | |
dc.contributor.author | Cid-Silva, Purificación | |
dc.contributor.author | Dueñas, Carlos | |
dc.contributor.author | Garcinuño, María Ángeles | |
dc.contributor.author | Lorenzo, Juan Francisco | |
dc.contributor.author | Margusino-Framiñán, Luis | |
dc.contributor.author | Quiñones, Marina | |
dc.contributor.author | Grande, Carmen | |
dc.contributor.author | Rodríguez-Osorio, Iria | |
dc.contributor.author | Castro-Iglesias, Ángeles | |
dc.date.accessioned | 2019-01-17T09:09:59Z | |
dc.date.issued | 2019-01-03 | |
dc.identifier.citation | Mena Á, Cid P, Dueñas C, et al. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy. HIV Clin Trials. 2018; 19(5): 197-201 | es_ES |
dc.identifier.issn | 1528-4336 | |
dc.identifier.uri | http://hdl.handle.net/2183/21598 | |
dc.description.abstract | [Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in patients under mono or dual therapy. METHODS: This was a prospective multicenter cohort study of patients using DRV/r under mono or dual therapy plus lamivudine who changed to DRV/c maintaining the previous regimen. All patients had a controlled HIV viral load (<50 copies/ml) when switched and were examined every 12 weeks. The primary end-point was the percentage of participants without virological failure (VF) at week 48 in the intent-to-treat analysis. The CD4 cell count and concentrations of cholesterol, triglyceride, and creatinine were measured from baseline to week 48. RESULTS: A total of 162 patients were included: 68.5% were men, and their mean age was 46 ± 12 years. Seventy (43.2%) patients were treated with DRV/r monotherapy, and 92 (56.8%) were treated with DRV/r plus lamivudine. The efficacy at week 48 was 95.1% (95% CI: 90.6%-97.5%) in the intent-to-treat analysis and 98.7% (95.5-99.6%) in the on-treatment analysis. Two VFs were documented but without development of resistance mutations. No significant changes were found in the lipid profile. Creatinine concentration increased significantly by 0.07 mg/dl (0.04-0.10, P < 0.001). CONCLUSIONS: Switching from DRV/r to DRV/c in patients under mono or dual therapy is safe and effective. | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III; JR17/00028 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Taylor & Francis | es_ES |
dc.relation.uri | https://doi.org/10.1080/15284336.2018.1513974 | es_ES |
dc.rights | This is an accepted manuscript of an article published by Taylor & Francis in HIV Clinical Trials on 2019, avaliable online in Taylor & Francis Online web page. | es_ES |
dc.subject | Darunavir/cobicistat | es_ES |
dc.subject | Dual therapy | es_ES |
dc.subject | Monotherapy | es_ES |
dc.subject | Pharmacokinetics | es_ES |
dc.title | Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/embargoedAccess | es_ES |
dc.date.embargoEndDate | 2020-01-03 | es_ES |
dc.date.embargoLift | 2020-01-03 | |
UDC.journalTitle | HIV Clinical Trials | es_ES |
UDC.volume | 19 | es_ES |
UDC.issue | 5 | es_ES |
UDC.startPage | 197 | es_ES |
UDC.endPage | 201 | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-VC - Artigos [37]